Trademarkia Logo

Australia

AU$
ZENROSIB
Accepted: In opposition period

Last updated on 6 Jun 2025

Owner Info

Nuvalent, Inc.

One Broadway, 14th Floor

Cambridge MA 02142, UNITED STATES OF AMERICA

Serial Number

2551894 filed on 18 Apr 2025

Correspondent

Joshua S. Jarvis Foley Hoag LLP

155 Seaport Blvd.,

Boston MA 02210-2600,

UNITED STATES OF AMERICA

ZENROSIB

Classification Information


Class [005]
Pharmaceutical preparations and pharmaceutical products for use in oncology diseases and disorders.

Mark Details


Serial Number

2551894

Registered On

NA

Renewal On

NA

Mark Type

WORD

Priority Claim (Convention Details)


Date

27 Nov 2024

Mark Type

US

Legal History


Show more

Status DateAction Taken
6th Jun 2025Application Accepted correspondence sent
5th Jun 2025IP Right has been Examined
5th Jun 2025IP Right Acceptance Published
5th Jun 2025Status change to Accepted
4th Jun 2025Awaiting examination
4th Jun 2025Examination expedited
29th May 2025IP Right Filed Published
29th May 2025Status change to Published
29th May 2025Status change to Filed
29th May 2025Application Received